Evidence map›Paper›PMID 25225910›Full record

ArticlePloS one2014

Oral immunization of mice with gamma-irradiated Brucella neotomae induces protection against intraperitoneal and intranasal challenge with virulent B. abortus 2308.

Neha Dabral, Martha-Moreno-Lafont, Nammalwar Sriranganathan, Ramesh Vemulapalli

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Protection against virulentClinical and experimental vaccine research · 2022
    Article
  7. Review
  8. Heliyon · 2021
    Article
  9. Radiation-InactivatedVaccines · 2021
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Immune Response to MucosalFrontiers in immunology · 2019
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Frontiers in microbiology · 2016
    Article
  20. Application of radiation technology in vaccines development.Clinical and experimental vaccine research · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Neha DabralDepartment of Comparative Pathobiology, College of Veterinary Medicine, Purdue University, West Lafayette, Indiana, United States of America.
Martha-Moreno-LafontDepartment of Comparative Pathobiology, College of Veterinary Medicine, Purdue University, West Lafayette, Indiana, United States of America; Departamento de Inmunología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Mexico City, Mexico.
Nammalwar SriranganathanDepartment of Biomedical Sciences and Pathobiology, Virginia-Maryland Regional College of Veterinary Medicine, Virginia Tech, Virginia, United States of America.
Ramesh VemulapalliDepartment of Comparative Pathobiology, College of Veterinary Medicine, Purdue University, West Lafayette, Indiana, United States of America.
Purdue University West Lafayette · USInstituto Politécnico Nacional · MXVirginia Tech · US

Funding

Non-replicative Vaccine for Human BrucellosisR01AI065667 · NIAID · PURDUE UNIVERSITY · PI VEMULAPALLI, RAMESH · 2008 to 2011
$1.2M
NIAID NIH HHS AI065667-01A2NIAID NIH HHS R01 AI065667
6 · The paper itself

Abstract

Brucella spp. are Gram-negative, facultative intracellular coccobacilli that cause one of the most frequently encountered zoonosis worldwide. Humans naturally acquire infection through consumption of contaminated dairy and meat products and through direct exposure to aborted animal tissues and fluids. No vaccine against brucellosis is available for use in humans. In this study, we tested the ability of orally inoculated gamma-irradiated B. neotomae and B. abortus RB51 in a prime-boost immunization approach to induce antigen-specific humoral and cell mediated immunity and protection against challenge with virulent B. abortus 2308. Heterologous prime-boost vaccination with B. abortus RB51 and B. neotomae and homologous prime-boost vaccination of mice with B. neotomae led to the production of serum and mucosal antibodies specific to the smooth LPS. The elicited serum antibodies included the isotypes of IgM, IgG1, IgG2a, IgG2b and IgG3. All oral vaccination regimens induced antigen-specific CD4(+) and CD8(+) T cells capable of secreting IFN-γ and TNF-α. Upon intra-peritoneal challenge, mice vaccinated with B. neotomae showed the highest level of resistance against virulent B. abortus 2308 colonization in spleen and liver. Experiments with different doses of B. neotomae showed that all tested doses of 10(9), 10(10) and 10(11) CFU-equivalent conferred significant protection against the intra-peritoneal challenge. However, a dose of 10(11) CFU-equivalent of B. neotomae was required for affording protection against intranasal challenge as shown by the reduced bacterial colonization in spleens and lungs. Taken together, these results demonstrate the feasibility of using gamma-irradiated B. neotomae as an effective and safe oral vaccine to induce protection against respiratory and systemic infections with virulent Brucella.

Indexed as

Gamma RaysAdministration, IntranasalAnimalsAntibodies, BacterialAntigens, BacterialBrucellaBrucella abortusBrucella VaccineBrucellosisCross ReactionsDisease Models, AnimalEpitopes, B-LymphocyteFemaleImmunizationImmunoglobulin IsotypesInjections, IntraperitonealAntibodies, BacterialAntigens, BacterialBrucella VaccineEpitopes, B-LymphocyteImmunoglobulin Isotypes

Identifiers

PMID25225910
PMCPMC4166413
OpenAlexW2011070423

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.